Westdeutsche Studiengruppe GmbH (WSG) / Women's healthcare Study Group

Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy (2023) Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, et al. Journal article, Review article PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant (2023) Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, et al. Journal article The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C (2022) De Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, Kates R, et al. Journal article Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, et al. Conference contribution Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al. Journal article Documentation Behavior in the CANKADO eHealth-Application and Effects on observed Side Effects - An exploratory Analysis of the PreCycle-Study (2020) Schmidt M, Degenhardt T, Fasching P, Wurstlein R, Lueftner D, Kates RE, Schumacher J, et al. Conference contribution Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014) (2017) Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, et al. Journal article Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial (2016) Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, et al. Journal article Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial (2015) Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, et al. Journal article Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (2014) Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, et al. Journal article